RUNX2 and lung carcinoma: RUNX2 appears to be an inferior prognostic biomarker in cohorts of patients with glioma, colorectal cancer, stomach cancer, pancreatic cancer, renal cancer, urothelial cancer, lung cancer, and cervical cancer.